South & Central America Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class and Type

The South & Central America vaccine adjuvants market was valued at US$ 100.04 million in 2022 and is expected to reach US$ 284.89 million by 2030; it is estimated to register a CAGR of 14.0% from 2022 to 2030.

Advancements in Biotechnology and Immunology Fuel South & Central America Vaccine Adjuvants Market

The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.

South & Central America Vaccine Adjuvants Market Overview

The South & Central America vaccine adjuvant market has been segmented into Brazil, Argentina, and the Rest of South & Central America. According to the Public Library of Science (PLOS) report, the use of adjuvants in vaccines is a key strategy for increasing immunity among the Brazilian population. Manufacturing adjuvanted vaccines is considered preparedness for public health emergencies such as pandemics. Therefore, the Brazilian government supports the production of adjuvanted vaccines. For example, Brazilian-manufactured "Oil-in-Water Emulsions" have revealed effective and safe adjuvanted vaccines to induce immune responses toward influenza antigens. The production of an adjuvanted vaccine for influenza in Brazil is conducted by the Butantan Institute, a public São Paulo State Institution, and the industrial infrastructure is capable of producing both seasonal and pandemic influenza adjuvanted vaccines.

South & Central America Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Vaccine Adjuvants Market Segmentation

The South & Central America vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the South & Central America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the South & Central America vaccine adjuvants market share in 2022.

By type, the South & Central America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of South & Central America vaccine adjuvants market in 2022.

By country, the South & Central America vaccine adjuvants market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; GSK Plc; Novavax Inc; and Phibro Animal Health Corp are some of the leading companies operating in the South & Central America vaccine adjuvants market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America vaccine adjuvants market.
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America vaccine adjuvants market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.